Luis Brieva Ruiz

de la Maza, SS; Maurino, J; Castillo-Triviño, T; Borges, M; Torres, BS; Sotoca, J; Torres, AMA; Caminero, AB; Borrega, L; Sánchez-Menoyo, JL; Barrero-Hernández, FJ; Calles, C; Brieva, L; Blasco, MR; García-Soto, JD; Rodríguez-Regal, A; Navarro-Cantó, L; Agüera-Morales, E; Garcés, M; Carmona, O; Gabaldón-Torres, L; Forero, L; Hervás, M; Gómez-Ballesteros, R

Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis

Patient Preference And Adherence 17 1431-1439. 01/01/2023.

[doi:10.2147/PPA.S411069]

Río J.; Peña J.; Brieva L.; García-Domínguez J.M.; Rodríguez-Antigüedad A.; Oreja-Guevara C.; Costa-Frossard L.; Arroyo R.

Monitoring response to disease-modifying treatment in multiple sclerosis

Neurology Perspectives 3 -. 01/01/2023.

[doi:10.1016/j.neurop.2023.100119]

Saposnik, Gustavo; Andhavarapu, Sanketh; Sainz de la Maza S; Castillo-Trivino, Tamara; Borges, Monica; Baron, Beatriz Pardinas; Sotoca, Javier; Alonso, Ana; Caminero, Ana B.; Borrega, Laura; Sanchez-Menoyo, Jose L.; Barrero-Hernandez, Francisco J.; Calles, Carmen; Brieva, Luis; Blasco, Maria R.; -Soto, Julio Dotor Garcia; del Campo-Amigo, Maria; Navarro-Canto, Laura; Agüera E; Garces, Moises; Carmona, Olga; Gabaldon -Torres, Laura; Forero, Lucia; Hervas, Mariona; Garcia-Arcelay, Elena; Terzaghi, Maria; Gomez-Ballesteros, Rocio; Maurino, Jorge

Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosis.

Multiple Sclerosis and Related Disorders 68 104138-104138. 01/12/2022.

[doi:10.1016/j.msard.2022.104138]

González-Mingot, C; Gil-Sánchez, A; Canudes-Solans, M; Peralta-Moncusi, S; Solana-Moga, MJ; Brieva-Ruiz, L

Preventive treatment can reverse cognitive impairment in chronic migraine

JOURNAL OF HEADACHE AND PAIN 23 -. 01/12/2022.

[doi:10.1186/s10194-022-01486-w]

Meca-Lallana, J E; Fernandez-Prada, M; Garcia Vazquez, E; Moreno Guillen, S; Otero Romero, S; Rus Hidalgo, M; Villar Guimerans, L M; Eichau Madueño S; Fernandez Fernandez, O; Izquierdo Ayuso, G; Álvarez Cermeño JC; Arnal Garcia, C; Arroyo Gonzalez, R; Brieva Ruiz, L; Calles Hernandez, C; Garcia Merino, A; Gonzalez Plata, M; Hernandez Perez, M A; Moral Torres, E; Olascoaga Urtaza, J; Oliva-Nacarino, P; Oreja-Guevara, C; Ortiz Castillo, R; Oterino, A; Prieto Gonzalez, J M; Ramio-Torrenta, L; Rodriguez-Antiguedad, A; Saiz, A; Tintore, M; Montalban Gairin, X

Consensus statement on the use of alemtuzumab in daily clinical practice in Spain.

NEUROLOGIA 37 615-630. 01/10/2022.

[doi:10.1016/j.nrleng.2019.11.001]

Solari, A; Montalban, X; Lechner-Scott, J; Piehl, F; Brochet, B; Langdon, D; Hupperts, R; Selmaj, K; Havrdova, EK; Patti, F; Brieva, L; Maida, EM; Alexandri, N; Smyk, A; Nolting, A; Keller, B

Improvements in quality of life over 2 years in patients treated with cladribine tablets for highly active relapsing multiple sclerosis: Final analysis of CLARIFY-MS

MULTIPLE SCLEROSIS JOURNAL 28 203-204. 01/10/2022.

Martín-Aguilar L.; Presas-Rodriguez S.; Rovira À.; Capellades J.; Massuet-Vilamajó A.; Ramió-Torrentà L.; Tintoré M.; Brieva-Ruiz L.; Moral E.; Cano-Orgaz A.; Blanco Y.; Batlle-Nadal J.; Carmona O.; Gea M.; Hervás-García J.V.; Ramo-Tello C.

Gadolinium-enhanced brain lesions in multiple sclerosis relapse

NEUROLOGIA 37 557-563. 01/09/2022.

[doi:10.1016/j.nrl.2021.10.005]

Castillo-Trivino, Tamara; Gomez-Ballesteros, Rocio; Borges, Monica; Martin-Martinez, Jesus; Sotoca, Javier; Alonso, Ana; Caminero, Ana B.; Borrega, Laura; Sanchez-Menoyo, Jose L.; Barrero-Hernandez, Francisco J.; Calles, Carmen; Brieva, Luis; Blasco-Quilez, Maria R.; Garcia-Soto, Julio Dotor; del Campo-Amigo, Maria; Navarro-Canto, Laura; Aguera, Eduardo; Garces-Redondo, Moises; Carmona, Olga; Gabaldon-Torres, Laura; Forero, Lucia; Hervas, Mariona; Mauriño J; Sainz de la Maza S

Long-term prognosis communication preferences in early-stage relapsing-remitting multiple sclerosis.

Multiple Sclerosis and Related Disorders 64 103969-103969. 01/08/2022.

[doi:10.1016/j.msard.2022.103969]

Gonzalez-Mingot, C; Lopez-Ortega, R; Brieva-Ruiz, L

The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2

NEUROLOGICAL SCIENCES 43 5099-5101. 01/08/2022.

[doi:10.1007/s10072-022-06144-2]

Brieva, L; Estruch, BC; Merino, JAG; Meca-Lallana, V; Rio, J; Rodriguez-Antigueedad, A; Aguera, E; Ara, JR; Luque, AA; Garcia, CA; Blanco, Y; Castillo-Trivino, T; Costa-Frossard, L; Platas, MG; Pascual, LL; Llaneza-Gonzalez, M; Gines, MLM; Matias-Guiu, J; Meca-Lallana, JE; Bilbao, MM; Sempere, AP; Romero-Pinel, L; Saiz, A; Moral, E

Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology

Multiple Sclerosis and Related Disorders 63 -. 01/07/2022.

[doi:10.1016/j.msard.2022.103805]

Vermersch P; Brieva-Ruiz L; Fox RJ; Paul F; Ramio-Torrenta L; Schwab M; Moussy A; Mansfield C; Hermine O; Maciejowski M

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.

Neurology-Neuroimmunology & Neuroinflammation 9 -. 01/05/2022.

[doi:10.1212/NXI.0000000000001148]

Sancho-Saldana, A; Gil Sánchez A; Quirant-Sanchez, B; Nogueras, L; Peralta, S; Solana, MJ; Gonzalez-Mingot, C; Gallego, Y; Quibus, L; Ramo-Tello, C; Presas-Rodriguez, S; Martinez-Caceres, E; Torres, P; Hervas, JV; Valls, J; Brieva, L

Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies.

Journal of Clinical Medicine 11 -. 29/04/2022.

[doi:10.3390/jcm11092509]